US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
US4275152A
(en)
|
1977-02-03 |
1981-06-23 |
Eastman Kodak Company |
Hydrolysis of protein-bound cholesterol esters
|
PT83613B
(en)
|
1985-10-28 |
1988-11-21 |
Lilly Co Eli |
Process for the selective chemical removal of a protein amino-terminal residue
|
JPS63502716A
(ja)
|
1986-03-07 |
1988-10-13 |
マサチューセッツ・インステチュート・オブ・テクノロジー |
糖タンパク安定性の強化方法
|
IN165717B
(ja)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
NZ232562A
(en)
|
1989-02-17 |
1992-10-28 |
Coselco Mimotopes Pty Ltd |
Immobilised peptide - solid support comprising a cleavable ester link between the peptide carboxy terminus and the solid support
|
CA2024855C
(en)
|
1990-09-07 |
1997-12-09 |
Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee |
Process and intermediates for producing glucagon
|
JPH04145099A
(ja)
|
1990-10-05 |
1992-05-19 |
Sanwa Kagaku Kenkyusho Co Ltd |
Gip様活性を有するポリペプチド誘導体及びその用途
|
US5510459A
(en)
|
1991-01-17 |
1996-04-23 |
Zymogenetics, Inc. |
Glucagon antagonists
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗hiv剤
|
US5359030A
(en)
|
1993-05-10 |
1994-10-25 |
Protein Delivery, Inc. |
Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
|
US5480867A
(en)
|
1993-12-29 |
1996-01-02 |
The Rockefeller University |
Glucagon analogs with serine replacements
|
US5512549A
(en)
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5691309A
(en)
|
1995-01-31 |
1997-11-25 |
Eli Lilly And Company |
Anti-obesity proteins
|
US5869602A
(en)
|
1995-03-17 |
1999-02-09 |
Novo Nordisk A/S |
Peptide derivatives
|
DE19530865A1
(de)
|
1995-08-22 |
1997-02-27 |
Michael Dr Med Nauck |
Wirkstoff sowie Mittel zur parenteralen Ernährung
|
EP0801557B1
(en)
|
1995-10-12 |
2003-07-02 |
Supergen, Inc. |
Liposome formulations of 5beta steroids
|
EP0879279A4
(en)
|
1996-02-06 |
2000-07-12 |
Lilly Co Eli |
DIABETE TREATMENT
|
IL128828A0
(en)
|
1996-09-09 |
2000-01-31 |
Zealand Pharmaceuticals As |
Peptide prodrugs containing an alpha-hydroxy acid linker
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
AU5518798A
(en)
|
1996-12-03 |
1998-06-29 |
Trustees Of Boston University |
Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
|
KR20010040819A
(ko)
|
1998-02-10 |
2001-05-15 |
가마꾸라 아끼오 |
제어방출형 제제
|
EP1062229A1
(en)
|
1998-03-09 |
2000-12-27 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
US20030236190A1
(en)
|
1998-09-02 |
2003-12-25 |
Renuka Pillutla |
Isulin and IGF-1 receptor agonists and antagonists
|
WO2000020592A1
(en)
|
1998-10-07 |
2000-04-13 |
Medical College Of Georgia Research Institute, Inc. |
Glucose-dependent insulinotropic peptide for use as an osteotropic hormone
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
AU3033500A
(en)
|
1999-01-15 |
2000-08-01 |
Agouron Pharmaceuticals, Inc. |
Non-peptide glp-1 agonists
|
GB0404124D0
(en)
|
2004-02-25 |
2004-03-31 |
Univ Ulster |
Antagonists of GIP
|
PT1171465E
(pt)
|
1999-03-29 |
2004-12-31 |
Uutech Ltd |
Analogos de petido inibidor gastrico e sua utilizacao para o tratamento de diabetes
|
US7601691B2
(en)
|
1999-05-17 |
2009-10-13 |
Conjuchem Biotechnologies Inc. |
Anti-obesity agents
|
EP1356295A2
(en)
|
2000-04-27 |
2003-10-29 |
Bionebraska, Inc. |
Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos
|
US6677136B2
(en)
|
2000-05-03 |
2004-01-13 |
Amgen Inc. |
Glucagon antagonists
|
US20030021795A1
(en)
|
2000-06-14 |
2003-01-30 |
Houston Michael E. |
Use of coiled-coil structural scaffold to generate structure-specific peptides
|
DK1294757T3
(da)
|
2000-06-16 |
2007-03-19 |
Lilly Co Eli |
Glucagonlignende peptid 1-analoger
|
BR0113178A
(pt)
|
2000-08-02 |
2004-04-06 |
Theratechnologies Inc |
Peptìdeos biológicos modificados com potência aumentada
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
US6846831B2
(en)
|
2000-08-15 |
2005-01-25 |
Cpd, Llc |
Method of treating the syndrome of lipodystrophy
|
US20020045572A1
(en)
|
2000-08-15 |
2002-04-18 |
Cpd, Llc |
Method of treating the syndrome of type 2 diabetes in humans
|
US6262062B1
(en)
|
2000-08-15 |
2001-07-17 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
ES2367891T3
(es)
|
2000-09-29 |
2011-11-10 |
Schering Corporation |
Interleucina-10 pegilada.
|
AU2002228608A1
(en)
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
DE60228972D1
(de)
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
AU2002327430A1
(en)
|
2001-08-08 |
2003-02-24 |
Genzyme Corporation |
Methods for treating diabetes and other blood sugar disorders
|
KR100593348B1
(ko)
|
2001-08-23 |
2006-06-26 |
일라이 릴리 앤드 캄파니 |
글루카곤-유사 펩티드-1 유사체
|
CN1635900A
(zh)
|
2001-08-28 |
2005-07-06 |
伊莱利利公司 |
Glp-1和基础胰岛素的预混合物
|
GB0121709D0
(en)
|
2001-09-07 |
2001-10-31 |
Imp College Innovations Ltd |
Food inhibition agent
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
US7041646B2
(en)
|
2001-10-05 |
2006-05-09 |
Bayer Pharmaceuticals Corporation |
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
|
EP1572892A4
(en)
|
2001-10-18 |
2007-08-22 |
Bristol Myers Squibb Co |
HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS
|
CN1571676A
(zh)
|
2001-10-19 |
2005-01-26 |
伊莱利利公司 |
Glp-1和胰岛素的双相混合物
|
AU2002351752A1
(en)
|
2001-12-29 |
2003-07-30 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
JP4282485B2
(ja)
|
2002-01-08 |
2009-06-24 |
イーライ リリー アンド カンパニー |
伸長グルカゴン様ペプチド−1アナログ
|
US20030232761A1
(en)
|
2002-03-28 |
2003-12-18 |
Hinke Simon A. |
Novel analogues of glucose-dependent insulinotropic polypeptide
|
AU2003239478A1
(en)
|
2002-06-04 |
2003-12-22 |
Eli Lilly And Company |
Modified glucagon-like peptide-1 analogs
|
AU2003237933A1
(en)
|
2002-06-11 |
2003-12-22 |
Cellartis Ab |
Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
|
US20040029805A1
(en)
|
2002-06-15 |
2004-02-12 |
Wolfe M. Michael |
Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
|
JP2006501820A
(ja)
|
2002-09-06 |
2006-01-19 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
修飾glp−1受容体アゴニストおよびそれらの薬理学的使用法
|
AU2003279842A1
(en)
|
2002-10-04 |
2004-05-04 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
US7192922B2
(en)
|
2002-11-19 |
2007-03-20 |
Allegheny-Singer Research Institute |
Method of treating left ventricular dysfunction
|
AU2004204494B2
(en)
|
2003-01-09 |
2011-09-29 |
Macrogenics, Inc. |
Identification and engineering of antibodies with variant Fc regions and methods of using same
|
US20050059605A1
(en)
|
2003-01-31 |
2005-03-17 |
Krishna Peri |
Chemically modified metabolites of regulatory peptides and methods of producing and using same
|
WO2004078777A2
(en)
|
2003-03-04 |
2004-09-16 |
Biorexis Pharmaceutical Corporation |
Dipeptidyl-peptidase protected proteins
|
AU2004231461B2
(en)
|
2003-03-19 |
2009-11-12 |
Eli Lilly And Company |
Polyethelene glycol linked GLP-1 compounds
|
DK1620118T3
(da)
|
2003-04-08 |
2014-09-29 |
Yeda Res & Dev |
Reversible pegylerede lægemidler
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
EP1633384B1
(en)
|
2003-05-15 |
2012-03-14 |
Trustees Of Tufts College |
Stable analogs of glp-1
|
CA2527743A1
(en)
|
2003-06-03 |
2004-12-09 |
Novo Nordisk A/S |
Stabilized pharmaceutical peptide compositions
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー/エス |
安定化された薬学的ペプチド組成物
|
ATE525395T1
(de)
|
2003-06-12 |
2011-10-15 |
Lilly Co Eli |
Fusions proteine von glp-1-analoga
|
US20050124550A1
(en)
|
2003-06-18 |
2005-06-09 |
Peri Krishna G. |
Compounds that modulate the glucagon response and uses thereof
|
EP1670515A2
(en)
|
2003-09-19 |
2006-06-21 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US7364875B2
(en)
|
2003-10-30 |
2008-04-29 |
Cresent Innovations, Inc. |
Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
|
EP1704165B1
(en)
|
2003-12-18 |
2010-03-17 |
Novo Nordisk A/S |
Glp-1 compounds
|
US20060286129A1
(en)
|
2003-12-19 |
2006-12-21 |
Emisphere Technologies, Inc. |
Oral GLP-1 formulations
|
US20080318837A1
(en)
|
2003-12-26 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
|
EA200701362A1
(ru)
|
2004-12-22 |
2008-08-29 |
Сентокор, Инк. |
Агонисты glp-1, композиции, способы и применения
|
JP2008530130A
(ja)
|
2005-02-11 |
2008-08-07 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Gip類似体および選択可能な特性を備えるハイブリッドポリペプチド
|
US20090062192A1
(en)
|
2005-03-18 |
2009-03-05 |
Novo Nordisk A/S |
Dimeric Peptide Agonists of the Glp-1 Receptor
|
WO2006121904A1
(en)
|
2005-05-06 |
2006-11-16 |
Bayer Pharmaceuticals Corporation |
Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
|
ATE482724T1
(de)
|
2005-05-13 |
2010-10-15 |
Lilly Co Eli |
Pegylierte glp-1-verbindungen
|
KR101349808B1
(ko)
|
2005-06-13 |
2014-02-13 |
임페리얼 이노베이션스 리미티드 |
섭취행동에 관한 신규 화합물들 및 이들의 효능
|
CA2617649A1
(en)
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
AU2006289259A1
(en)
|
2005-09-08 |
2007-03-15 |
Uutech Limited |
Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
|
EP1943274A2
(en)
|
2005-09-08 |
2008-07-16 |
Uutech Limited |
Treatment of diabetes related obesity
|
EP2497781A1
(en)
|
2005-09-08 |
2012-09-12 |
Trustees Of Tufts College |
Stabilized GLP-1 analogs
|
US7846445B2
(en)
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
EP2471811B1
(en)
|
2006-02-22 |
2015-09-16 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin derivatives
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
JP5412273B2
(ja)
|
2006-03-21 |
2014-02-12 |
アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー |
ペプチド−ぺプチダーゼ阻害剤及びその使用
|
EP2574624A1
(en)
|
2006-04-20 |
2013-04-03 |
Amgen Inc. |
GLP-1 compounds
|
CA2651283A1
(en)
|
2006-05-15 |
2007-11-22 |
Wisconsin Alumni Research Foundation |
Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
|
FR2902092B1
(fr)
|
2006-06-07 |
2008-09-05 |
Sapelem Soc Par Actions Simpli |
Appareil de manutention de charge
|
WO2008022015A2
(en)
|
2006-08-11 |
2008-02-21 |
Trustees Of Tufts College |
Retro-inverso incretin analogues, and methods of use thereof
|
WO2008021560A2
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable properties
|
WO2008023050A1
(en)
|
2006-08-25 |
2008-02-28 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
JP5840345B2
(ja)
|
2006-09-08 |
2016-01-06 |
アンブルックス, インコーポレイテッドAmbrx, Inc. |
修飾ヒト血漿ポリペプチドまたは修飾ヒトFc足場タンパク質ならびにこれらの利用
|
EP2102355B1
(en)
|
2006-12-14 |
2016-03-02 |
Bolder Biotechnology, Inc. |
Long acting proteins and peptides and methods of making and using the same
|
AU2008205229B2
(en)
|
2007-01-05 |
2014-03-27 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility in physiological pH buffers
|
AU2008216265B2
(en)
|
2007-02-15 |
2014-04-03 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
AU2008241699B2
(en)
|
2007-04-19 |
2011-02-03 |
Dong-A Pharmaceutical. Co., Ltd |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
MX2010001684A
(es)
|
2007-08-15 |
2010-04-21 |
Amunix Inc |
Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
|
CN101842386A
(zh)
|
2007-09-05 |
2010-09-22 |
诺沃-诺迪斯克有限公司 |
截短的glp-1衍生物和它们的治疗用途
|
EP2190872B1
(en)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
WO2009035540A2
(en)
|
2007-09-07 |
2009-03-19 |
Ipsen Pharma S.A.S. |
Analogues of exendin-4 and exendin-3
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
WO2009034117A1
(en)
|
2007-09-11 |
2009-03-19 |
Novo Nordisk A/S |
Mixture comprising an amylin peptide and a protracted insulin
|
EP2036923A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Improved derivates of amylin
|
CA2702289A1
(en)
*
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
MX2010004297A
(es)
|
2007-10-30 |
2010-05-03 |
Univ Indiana Res & Tech Corp |
Antagonistas de glucagon.
|
ES2448839T3
(es)
*
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
JP2011511778A
(ja)
|
2008-01-30 |
2011-04-14 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
エステルに基づいたペプチドプロドラッグ
|
CA2712224C
(en)
|
2008-02-01 |
2016-03-08 |
Ascendis Pharma As |
Prodrug comprising a drug linker conjugate
|
US8450270B2
(en)
|
2008-06-17 |
2013-05-28 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
|
CN104945500B
(zh)
*
|
2008-06-17 |
2019-07-09 |
印第安纳大学研究及科技有限公司 |
基于gip的混合激动剂用于治疗代谢紊乱和肥胖症
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
US20110212053A1
(en)
|
2008-06-19 |
2011-09-01 |
Dapeng Qian |
Phosphatidylinositol 3 kinase inhibitors
|
CA2738715C
(en)
*
|
2008-10-15 |
2013-07-16 |
Intarcia Therapeutics, Inc. |
Highly concentrated drug particles, formulations, suspensions and uses thereof
|
JP2012512898A
(ja)
*
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
ジペプチド結合薬用剤
|
JP2012512903A
(ja)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
|
WO2010096052A1
(en)
*
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
RU2012101274A
(ru)
|
2009-06-16 |
2013-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Соединения глюкагона, активные в отношении рецептора gip
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
WO2011075393A2
(en)
|
2009-12-18 |
2011-06-23 |
Indiana University Research And Technology Corporation |
Glucagon/glp-1 receptor co-agonists
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
WO2011094337A1
(en)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
|
AR080592A1
(es)
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
CN103179976A
(zh)
|
2010-05-13 |
2013-06-26 |
印第安纳大学研究及科技有限公司 |
呈现g蛋白偶联受体活性的胰高血糖素超家族肽
|
EP2569000B1
(en)
*
|
2010-05-13 |
2017-09-27 |
Indiana University Research and Technology Corporation |
Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
|
KR20130102470A
(ko)
|
2010-06-24 |
2013-09-17 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|